{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-071061","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2024-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.331350+00:00","generated_at":"2026-05-31T08:29:08.250832+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"InMed confirms INM-901 oral formulation for Alzheimer's; bioavailability comparable to injection","bullets":["Preclinical data show oral INM-901 achieves similar brain drug levels as intraperitoneal (IP) injection over 24h.","Oral delivery offers potential advantages over IV large-molecule antibody therapies, including lower cost and easier access.","INM-901 is a proprietary small molecule that crosses the blood-brain barrier via GI absorption.","Company conducting CMC, drug metabolism, dose-ranging, and PK studies to support IND submission.","Current disease-modifying Alzheimer's treatments require IV infusion every 2-4 weeks at medical facilities."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-071061","json":"https://secwatch.observer/filing/0001213900-24-071061.json","markdown":"https://secwatch.observer/filing/0001213900-24-071061.md","text":"https://secwatch.observer/filing/0001213900-24-071061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024071061/0001213900-24-071061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024071061/ea0211922-8k_inmed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:29:08.250832+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}